Mentice (MNTC) Q4 2024 earnings summary

Executive summary

• Q4 2024 saw net sales rise 22.4% year-over-year, with strong performance in EMEA and APAC, and stable results in North America.

• EBITDA margin reached 19.1% for the quarter, with a net profit of SEK 2 million.

• Full-year 2024 net sales rose 6.1% to SEK 290.3 million, with organic growth of 5.3%.

• Order intake for Q4 increased 4.7% but declined 8% for the full year.

• CEO transition announced: Frans Venker appointed as new CEO effective January 1, 2025.

Financial highlights

• Q4 net sales: SEK 86.2 million (+22.4% year-over-year); full-year net sales: SEK 290.3 million (+6.1%).

• Q4 EBITDA: SEK 16.6 million; adjusted Q4 EBITDA: SEK 24.1 million.

• Full-year EBITDA: SEK 16.6 million; adjusted full-year EBITDA: SEK 24.1 million.

• Operational cash flow for the year at nearly SEK 18 million, about half of 2023's level.

• Gross margin for Q4: 88.8%; full-year: 88.7%, improved by higher software sales and hardware cost efficiencies.

Outlook and guidance

• Focus for 2025 is on accelerating growth in the Americas and advancing hospital and Medical Device Industry segments.

• Continued innovation and integration of Neurovascular Connect and VIST Ankyras platforms expected to drive growth.

• Emphasis on expanding software licenses and recurring revenue streams.

• R&D investments to maintain technology leadership and optimize efficiency.

• Short- to medium-term targets: 20–30% annual net sales growth and 20% EBITDA margin within three years.